Goodsurance

Drug prices & Part D

CMS Proposes Making Medicare Drug Price Negotiations a Permanent Federal Regulation

A proposed rule published June 16, 2026, would replace the program's expiring guidance authority with binding regulation covering negotiations starting with the 2029 price year.

By the Goodsurance editorial teamJuly 8, 2026

The Centers for Medicare and Medicaid Services published proposed rule CMS-4215-P in the Federal Register on June 16, 2026, to establish a durable regulatory framework for Medicare's drug price negotiation program. The proposal covers initial price applicability year 2029 and every cycle thereafter.

The Inflation Reduction Act of 2022 created the negotiation program and authorized CMS to operate the first three cycles, with prices taking effect in 2026, 2027, and 2028, through administrative guidance rather than formal rulemaking. That authority expires after the 2028 cycle.

CMS wants to lock drug price negotiations into permanent federal rules. The public has until August 17, 2026, to weigh in.

CMS-4215-P would codify each phase of the program: drug selection and ranking, manufacturer agreement requirements, the offer-and-counteroffer process, renegotiation criteria, and publication of maximum fair prices.

The third negotiation cycle, covering 15 drugs with prices effective January 1, 2028, is currently under way. All 15 manufacturers chose to participate.

The comment period closes August 17, 2026. Comments may be submitted at regulations.gov. CMS expects to finalize the rule in fall 2026 in time to govern the 2029 cycle.

In plain words

Medicare can negotiate prices on some expensive drugs because of a 2022 law. Until now the rules for how this works came from CMS instructions, not formal regulations. That was what the law allowed for the first three rounds of talks, which cover prices through 2028. Now CMS wants to make those rules permanent. It published a proposed regulation in June 2026. The new rule would explain how CMS picks drugs, how talks with drug companies work, and how final prices are set. It would apply starting in 2029. Anyone can send comments to the government until August 17, 2026.

Source: Federal Register
Read at the source →

More news

Other stories on what is moving in Medicare.

Drug prices & Part D

OIG Report Finds Medicare Part B Drug Price-Substitution Mechanism Saved 1.6 Million Dollars in 2024

An annual OIG analysis posted Wednesday found CMS applied price reductions to 14 physician-administered drugs based on 2024 market data, while reporting that errors in manufacturer price submissions blocked the review of 31 additional drugs.

September 24, 2026

Drug prices & Part D

CMS Must Send Final Written Price Offers to 15 Drug Makers by September 30 in Third Negotiation Cycle

The final statutory step before drug manufacturers accept or reject Medicare prices arrives this week. CMS must issue written maximum fair price offers by September 30, and manufacturers have until October 31 to respond. Agreed prices would take effect in 2028.

September 23, 2026

Drug prices & Part D

About 140,000 Wellcare Part D Members Were Dropped Mid-Year After Small New Premiums Were Added to Their Previously Free Plans

KFF Health News found that Wellcare terminated tens of thousands of drug plan members in April 2026 when minimal monthly premiums went unpaid, leaving many without prescription coverage and at risk for permanent Medicare drug enrollment penalties.

September 21, 2026

Drug prices & Part D

MedPAC September Meeting Finds IRA Changes Improved Drug Affordability for Enrollees but May Be Accelerating Overall Medicare Part D Spending

Medicare's congressional advisory commission opened its new study cycle in September finding that Inflation Reduction Act drug benefit changes have helped individual beneficiaries while putting upward pressure on total program spending and future premiums.

September 20, 2026

Drug prices & Part D

Medicare's 2027 Part D Base Beneficiary Premium Will Be 41 Dollars and 33 Cents, Hitting the Inflation Reduction Act's Annual Cap

CMS set the 2027 Part D base beneficiary premium at 41 dollars and 33 cents in July, representing a 6 percent rise from the prior year and the maximum the IRA allows, a benchmark that shapes what drug plans charge as open enrollment approaches.

September 19, 2026

Drug prices & Part D

Federal Watchdog Adds Medicare Part D GLP-1 Overdispensing to Its Active Study List

The Office of Inspector General announced a new evaluation of GLP-1 prescribing patterns in Part D, as the Medicare obesity drug bridge program continues to attract enrollment.

September 17, 2026